Jefferies downgraded uniQure BV (NASDAQ: QURE) from Buy to Hold with a price target of $8.00 (from $28.00) on execution risk and lack of major near-term catalysts.

Analyst Eun Yang commented, "Once viewed as the most advanced gene therapy platform company (& landmark gene therapy deal w/ BMY in 2015), today QURE's position is overshadowed by lack of progress, competition & poor execution. Its strategic review & prioritization announced last wk comes up short in providing confidence in strategy/execution. In addition, with no apparent NT key catalysts, we move to Hold until we see a turnaround in execution."

For an analyst ratings summary and ratings history on uniQure BV click here. For more ratings news on uniQure BV click here.

Shares of uniQure BV closed at $7.13 yesterday.